Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity

DNA Repair

Volumn 9, Issue 12, 2010, Pages 1292-1298

  Evans, Terry John ^a   Yamamoto, Kimiyo N ^a   Hirota, Kouji ^a   Takeda, Shunichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

DNA damage; DNA repair; DT40; Genotoxicity assay; High throughput screening

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; DNA POLYMERASE; LUCIFERASE; MITOCHONDRIAL DNA; PROTEIN MLH1; PROTEIN MSH2;

AMES TEST; CANCER CELL DESTRUCTION; CANCER SUSCEPTIBILITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL MUTANT; CENTROMERE; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; DNA CROSS LINKING; DNA REPAIR; DNA REPLICATION; EXCISION REPAIR; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENETIC SCREENING; GENOMIC INSTABILITY; GENOTOXICITY; GERM LINE; HEREDITARY COLORECTAL CANCER; HIGH THROUGHPUT SCREENING; HOMOLOGOUS RECOMBINATION; HUMAN; INDUCED MUTATION; INTRACELLULAR KILLING; IONIZING RADIATION; MICRONUCLEUS TEST; MISMATCH REPAIR; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION MUTAGENESIS; REVIEW; SINGLE STRANDED DNA BREAK; SOMATIC CELL; WILD TYPE;

ANIMALS; CELL LINE; CHICKENS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; MUTAGENICITY TESTS; MUTAGENS; MUTATION;

EID: 78649443310     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2010.09.017     Document Type: Review

References (36)

1. Ji K., Kogame T., Choi K., Wang X., Lee J., Taniguchi Y., Takeda S. A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environmental Health Perspectives 2009, 117:1-9.
2. Buerstedde J.-M., Takeda S. Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 1991, 67:179-188.
3. Yamazoe M., Sonoda E., Hochegger H., Takeda S. Reverse genetic studies of the DNA damage resonse in the chicken B lymphocyte line DT40. DNA Repair (Amst) 2004, 3:1175-1185.
4. Neumann B., Walter T., Heriche J.K., Bulkescher J., Erfle H., Conrad C., Rogers P., Poser I., Held M., Liebel U., Cetin C., Sieckmann F., Pau G., Kabbe R., Wunsche A., Satapogam V., Schmitz M.H., Chapuis C., Gerlich D.W., Schneider R., Eils R., Huber W., Peters J.M., Hyman A.A., Durbin R., Pepperkok R., Ellenberg J. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature 2010, 464:721-727.
5. Kirkland D.J., Henderson L., Marzin D., Müller L., Parry J.M., Speit G., Tweats D.J., Williams G.M. Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes. Mutation Research 2005, 588:88-105.
6. Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). British Journal of Clinical Pharmacology 1994, 37:401-404.
7. Kirkland D.J., Hayashi M., Jacobson-Kram D., Kasper P., MacGregor J.T., Müller L., Uno Y. Summary of major conclusions from the 4th IWGT, San Francisco, 9-10 September, 2005. Mutation Research 2007, 627:5-9.
8. Kirkland D.J. The role of the UKEMS in the development of testing guidelines. Mutagenesis 2002, 17:451-455.
9. Kirkland D.J., Aardema M., Henderson L., Müller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutation Research 2005, 584:1-256.
10. Ashby J., Styles J.A. Does carcinogenic potency correlate with mutagenic potency in the Ames assay?. Nature 1978, 271:452-455.
11. Ames B.N., Gurney E.G., Miller J.A., Bartsch H. Carcinogens as frameshift mutagens: metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. Proceedings of the National Academy of Sciences of the United States of America 1972, 69:3128-3132.
12. Ames B.N., Durston W.E., Yamasaki E., Lee F.D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proceedings of the National Academy of Sciences of the United States of America 1973, 70:2281-2285.
13. Ames B.N., Lee F.D., Durston W.E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proceedings of the National Academy of Sciences of the United States of America 1973, 70:782-786.
14. Lawrence C.W. Cellular roles of DNA polymerase zeta and Rev1 protein. DNA Repair (Amst) 2002, 1:425-435.
15. Poirier M.C., Schild L.J. The genotoxicity of tamoxifen: extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis 2003, 18:395-399.
16. Mizutani A., Okada T., Shibutani S., Sonoda E., Hochegger H., Nishigori C., Miyachi Y., Takeda S., Yamazoe M. Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Research 2004, 64:3144-3147.
17. Harfe B.D., Jinks-Robertson S. DNA polymerase ζ introduces multiple mutations when bypassing spontaneous DNA damage in Saccharomyces cerevisiae. Molecular Cell 2000, 6:1491-1499.
18. Sonoda E., Okada T., Zhao G.Y., Tateishi S., Araki K., Yamaizumi M., Yagi T., Verkaik N.S., van Gent D.C., Takata M., Takeda S. Multiple roles of Rev3, the catalytic subunit of polζ in maintaining genome stability in vertebrates. The EMBO Journal 2003, 22:3188-3197.
19. Kirkland D.J., Aardema M., Banduhm N., Carmichael P., Fautz R., Meunier J.-R., Pfuhler S. In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. Mutagenesis 2007, 22:161-175.
20. Reviews and Protocols in DT40 Research 2006, Springer, New York. J.-M. Buerstedde, S. Takeda (Eds.).
21. Welch E.M., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
22. Auld D.S., Thorne N., Maguire W.F., Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3585-3590.
23. Abdullaev F.I., Rivera-Luna R., Garcia-Carranca A., Ayala-Fierro F., Espinosa-Aguirre J.J. Cytotoxic effect of three arsenic compounds in HeLa human tumor and bacterial cells. Mutation Research 2001, 493:31-38.
24. Kirkland D., et al. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop. Mutation Research 2007, 628:31-55.
25. Inglese J., Auld D.S., Jadhav A., Johnson R.L., Simeonov A., Yasgar A., Zheng W., Austin C.P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:11473-11478.
26. Xia M., Huang R., Witt K.L., Southall N., Fostel J., Cho M.-H., Jadhav A., Smith C.S., Inglese J., Portier C.J., Tice R.R., Austin C.P. Compound cytotoxicity profiling using quantitative high-throughput screening. Environmental Health Perspectives 2008, 116:284-291.
27. Kirsch-Volders M., Gonzalez L., Carmichael P., Kirkland D. Risk assessment of genotoxic mutagens with thresholds: a brief introduction. Mutation Research 2009, 678:72-75.
28. Crouch S.P.M., Kozlowski R., Slater K.J., Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. Journal of Immunological Methods 1993, 160:81-88.
29. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Proceedings of the National Academy of Sciences of the United States of America 2005, 434:913-917.
30. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M.B., Jackson S.P., Smith G.C.M., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America 2005, 434:917-921.
31. Jacob S., Praz F. DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimie 2002, 84:27-47.
32. Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka S., Kay E., Lord C.J., Ashworth A. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
33. Kumamoto-Yonezawa Y., Sasaki R., Suzuki Y., Matsui Y., Hada T., Uryu K., Sugimura K., Yoshida H., Mizushina Y. Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid-a mammalian DNA polymerase inhibitor. International Journal of Oncology 2010, 36:577-584.
34. Wang H., Wu W., Wang H.W., Wang S., Chen Y., Zhang X., Yang J., Zhao S., Ding H.F., Lu D. Analysis of specialized DNA polymerases expression in human gliomas: association with prognostic significance. Journal of Neuro-oncology 2010, 10.1093/neuonc/nop074.
35. Murphy C.G., Moynahan M.E. BRCA gene structure and function in tumour suppression: a repair-centric perspective. Cancer Journal 2010, 16:39-47.
36. Parry E.M., Parry J.M., Corso C., Doherty A., Haddad F., Hermine T.F., Johnson G., Kayani M., Quick E., Warr T., Williamson J. Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis 2002, 17:509-521.